Our Expert Videos

Locally advanced head and neck cancer patients that are ineligible for cisplatin face a variety of unmet needs, and disruptive innovation in radiation therapy could provide benefits for this population. Leading medical experts will discuss the company and its first-in-class radioenhancer NBTXR3, an aqueous suspension of crystalline hafnium oxide that, after intramural injection prior to a patient’s first radiation therapy session, increases the energy deposit from ionizing radiation within the cell without increasing the dose in surrounding healthy tissues.

Presentation R&D Day

Dr. James Welsh


Many tumors are not adequately responsive to checkpoint inhibitors and other IO approaches. Can we use radiation and nanoparticles to stimulate an immune response against a tumor? Watch video #5 to hear Dr. James Welsh to learn what advances are being developed in immunooncology, radiotherapy and nanomedicine.

Dr. Tanguy Seiwert


Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. Once in a while, we as researchers must try something new and has the potential to revolutionize the treatment landscape. The 1100 trial selects patients who have failed radiation and are not likely to be cured.Preclinical and clinical data suggest that NBTXR3 has the potential to turn CPI non-responders into responders, and that these nanoparticles help induce immunogenesis, turning “cold” tumors into “hot” ones, allowing the immune system to recognize the tumor and get equipped against it. Dr. Tanguy Seiwert maps out Nanobiotix’s Phase I/II 1100 trial studying the potential immunogenic effect of NBTXR3 in head & neck cancer and non-small cell lung cancer patients.

Laurent Levy, PHD


“20 years ago, I asked myself: Can we influence a cell by impacting its physics at the subcellular level?” Laurent Levy examines the importance of asking different questions, and how this leads to disruptive healthcare. This video presents how NBTXR3’s technology came into being, and the developments of NBTXR3 in clinical trials.

Multidisciplinary Head & Neck Symposium

Dr. Caroline Hoffmann

NBTXR3 Intratumoral Injection

“Intratumoral injection of NBTXR3 is feasible and safe and NBTXR3 remains localized within the tumor throughout RT treatment.”

Prof. Christophe Le Tourneau

Head & Neck cancer phase I trial

“Radiotherapy is the only option to treat this fragile H&N Cancer population and benefits are limited.”

Laurent Levy, PHD


“Changing the treatment paradigm for millions of patients by bringing nanophysics to the heart of the cell.”